Last updated: June 6, 2026
Suppliers for Tramadol Hydrochloride and Acetaminophen (Combination Tablets): Who Manufactures, Where They Source, and What IP/Regulatory Barriers Matter
Executive summary: Tramadol hydrochloride and acetaminophen combination tablets are typically supplied through (1) API makers for tramadol HCl and acetaminophen, (2) formulation and tablet contract manufacturers (CMOs) that compress and blend the combination product, and (3) distributors supplying finished dosage forms to wholesalers and PBM channels. Supplier selection is constrained by FDA approved manufacturing status, DMF availability for key excipients and intermediates, and whether the finished product is generic, branded, or authorized generic.
Data limits: A complete, accurate supplier map requires the specific marketed NDC(s) and strength (e.g., 37.5 mg/325 mg), because multiple branded/generic versions exist with different manufacturing sites, labeling, and Orange Book listings. Without identifying the exact product(s), listing specific suppliers risks mixing products with different approvals and manufacturing authorizations.
If you proceed with the specific NDC(s)/strength(s), a full supplier table can be produced (API suppliers, CMO sites, DMF holders, and finished-product manufacturing/labeler parties).
Which companies supply tramadol hydrochloride and acetaminophen APIs for combo tablets?
Short answer: API supply is typically split between specialist API manufacturers for tramadol HCl and bulk producers for acetaminophen, then combined by tablet CMOs or finished-dose manufacturers into tramadol/acetaminophen formulations.
Common upstream supply chain structure
- Tramadol hydrochloride API: produced under DMF/CEP-linked chemistries and shipped as API to formulation sites.
- Acetaminophen API: produced as bulk analgesic API with established global sourcing networks.
- Key excipient supply: microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and film-coat systems (when used) are frequently multi-sourced.
Featured snippet: What to verify in supplier qualification
- FDA status of the drug substance manufacturing (DMF coverage and supplier’s ability to support regulatory filings).
- Capability for powder handling and blending uniformity at scale.
- Analytical package: assay, impurities, residual solvents, and polymorph control for any sensitive intermediates.
- Supply continuity and controlled-substance compliance readiness for tramadol.
What finished-dose manufacturers supply tramadol HCl/acetaminophen tablets to the US market?
Short answer: Finished-dose supply is typically provided by generic manufacturers and their contract partners who hold ANDA approvals for the fixed-dose combination and list manufacturing sites in regulatory submissions.
What determines who can supply
- ANDA status and FDA labeling approval
- Orange Book listing for the exact strength and dosage form
- Current good manufacturing practices (CGMP) inspection outcomes
- Contract manufacturing: many labelers use one or more CMOs for compression, coating, and packaging
How to map “supplier” in a practical procurement view
- Labeler/Applicant (often different from actual factory)
- Manufacturing site(s) (tablet core and packaging)
- Packaging-only sites (where applicable)
- API sourcing constraints tied to DMF/quality agreements
What Orange Book status applies to tramadol hydrochloride and acetaminophen combination products?
Short answer: Multiple strengths and versions exist; Orange Book status depends on the exact marketed product strength and whether it is branded, generic, or authorized generic.
What the Orange Book typically shows for this class
- Patent listings covering:
- composition (fixed-dose combination)
- methods of use (where applicable)
- formulation/solid-state characteristics
- sometimes manufacturing or bioavailability-related details
Why Orange Book status matters for supplier selection
- It affects who can legally manufacture or switch to an alternative manufacturing route.
- It drives licensing and product release timing for CMOs serving multiple clients.
When do tramadol/acetaminophen combination products lose exclusivity, and what generic entry risks exist?
Short answer: Entry timing depends on the specific ANDA/brand version and listed exclusivities. For combination analgesics in long-established use, exclusivity is often not the binding constraint; patent families and site-specific manufacturing validity typically govern.
Paragraph IV challenge and settlement impacts
- If a challenger files under Paragraph IV, generic supply can be delayed pending litigation or settlement.
- Settlement terms frequently govern launch date, carve-outs, and product stewardship.
Procurement implication
- Supplier capacity plans should align to:
- expected launch windows tied to patent expiry
- risk of “design-around” formulations at the ANDA level
- court-adjudicated validity/enforcement outcomes affecting product availability
What patents protect tramadol hydrochloride and acetaminophen tablets, and how strong is the patent estate?
Short answer: Patent estates usually cover the combination dose form and sometimes formulation characteristics. For procurement and manufacturing planning, the actionable question is whether a supplier’s intended ANDA route is protected by enforceable patents.
Patent categories relevant to the combination
- Fixed-dose composition claims
- Formulation claims (granulation, excipient ratios, compression aids)
- Method-of-use claims (if listed for this product)
- Process/method claims (less common but relevant to certain route changes)
How “strength” is determined in practice
- Whether patents are:
- still listed and enforceable
- the subject of current litigation
- narrowed by claim construction
- implicated in injunction or settlement terms
What formulation patents affect tablet manufacture for tramadol HCl/acetaminophen?
Short answer: Tablet formulation patents, when present, most often cover specific excipient systems, dissolution/bioavailability related parameters, and solid-state attributes that affect performance.
Manufacturing/IP choke points
- Blending and compression parameters tied to bioequivalence
- Dissolution targets linked to patent specifications
- Use of specific excipient grades or coatings
- Granulation method and moisture control
Which contract manufacturing organizations (CMOs) can produce tramadol/acetaminophen tablets?
Short answer: CMOs that produce oral solid dose forms can generally compress tablets, but eligibility depends on:
- relevant ANDA/DMF capability for the specific combination
- handling controls for tramadol
- ability to document dissolution and impurity profiles consistent with approved dossiers
CPO/CMO due diligence points
- Capacity for high-volume analgesic tablets
- Controlled-substance security and chain-of-custody readiness
- Analytical lab support and stability programs for combination products
- Batch documentation systems aligned with FDA expectations
How does tramadol + acetaminophen supplier selection differ by strength and dosage form?
Short answer: Supplier qualification differs by strength and by whether the product is immediate-release tablet versus other forms (if present). The combination’s excipient system and release profile are strength-dependent.
Key procurement variables
- Tablet core composition and excipient ratio
- Dissolution profile alignment to the ANDA reference product
- Packaging system compatibility (blister vs bottle) and stability
- Labeling and imprint variations that can tie to specific approved manufacturing instructions
What regulatory documentation do suppliers need for tramadol/acetaminophen products?
Short answer: Suppliers must support FDA requirements through DMF and quality agreements, and finished-dose manufacturers must maintain CGMP compliance.
Typical documentation set
- DMF cross-reference (API and certain excipients)
- Certificates of analysis and impurity control strategy
- Stability data and storage condition compliance
- Validation of cleaning and cross-contamination controls (particularly for a controlled-substance-containing product)
Competitive landscape: How do supplier networks differ between generic labelers and brand owners?
Short answer: Brand owners rely on a tightly qualified global supply chain, while generic labelers often use multiple CMOs to manage supply risk, batch yields, and launch timing.
Where differentiation shows up
- number of qualified manufacturing sites
- redundancy for API supply and excipient supply
- ability to support label changes and manufacturing supplements quickly
Key Takeaways
- “Supplier” for tramadol hydrochloride and acetaminophen tablets breaks into API supply, CMO/formulation capacity, and finished-dose manufacturing/labeling.
- Supplier qualification hinges on FDA regulatory status (DMF/ANDA alignment), CGMP inspection history, controlled-substance handling, and formulation/dissolution package support.
- A complete supplier list by company requires the exact marketed strength and NDC(s) to avoid mixing different approvals and manufacturing sites.
- Patent and exclusivity status drives who can legally launch and who can run product lines without IP risk.
FAQs
- Which APIs are used to manufacture tramadol hydrochloride and acetaminophen tablets in the US?
- How do contract manufacturers qualify for producing tramadol-containing oral solid dose products?
- What documentation ties an API supplier to an ANDA (DMF cross-reference) for tramadol/acetaminophen?
- How do Orange Book patent listings affect procurement of generic tramadol/acetaminophen?
- What packaging suppliers (bottles/blisters) are commonly used for tramadol/acetaminophen generics?
References
No sources were cited because specific product strength/NDCs and corresponding FDA/Orange Book listings were not provided.
